Welcome to STN International! Enter x:X

LOGINID:SSSPTA1615LXC

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * *
NEWS	1			Web Page for STN Seminar Schedule - N. America
NEWS	2	APR	02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS	3	APR	02	PATDPAFULL: Application and priority number formats enhanced
NEWS	4	APR	0.2	DWPI: New display format ALLSTR available
NEWS	5	APR		New Thesaurus Added to Derwent Databases for Smooth
	-			Sailing through U.S. Patent Codes
NEWS	6	APR	02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS	7	APR	0.7	CA/CAplus CLASS Display Streamlined with Removal of
112110				Pre-IPC 8 Data Fields
NEWS	8	APR	0.7	50,000 World Traditional Medicine (WTM) Patents Now
112110		***		Available in CAplus
NEWS	9	APR	0.7	MEDLINE Coverage Is Extended Back to 1947
NEWS		JUN		WPI First View (File WPIFV) will no longer be
		0 011		available after July 30, 2010
NEWS	11	JUN	1.8	DWPI: New coverage - French Granted Patents
NEWS		JUN		CAS and FIZ Karlsruhe announce plans for a new
				STN platform
NEWS	13	JUN	18	IPC codes have been added to the INSPEC backfile (1969-2009)
NEWS	1.4	JUN	21	Removal of Pre-IPC 8 data fields streamline displays
MEMO	TA	0.014	21	in CA/CAplus, CASREACT, and MARPAT
NEWS	15	JUN	21	Access an additional 1.8 million records exclusively
MEMO	13	0014	21	enhanced with 1.9 million CAS Registry Numbers EMBASE Classic on STN
NEWS	16	JUN	28	Introducing "CAS Chemistry Research Report": 40 Years
				of Biofuel Research Reveal China Now Atop U.S. in Patenting and Commercialization of Bioethanol
NEWS	17	JUN	20	Enhanced Batch Search Options in DGENE, USGENE,
MEMO	1 /	JUN	23	and PCTGEN
NEWS	1.8	JUL	1.0	Enhancement of citation information in INPADOC
ишию	10	ООП	13	databases provides new, more efficient competitor
				analyses
NEWS	19	JUL	26	CAS coverage of global patent authorities has
ишию	10	ООП	20	expanded to 61 with the addition of Costa Rica
NEWS	20	SEP	0.9	New basic patent number increases precision in
112110		O.D.		retrieving records from USGENE
NUMBER	DVDI	anno.	DDD	RUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
NEWS	EAPI			RENT DISCOVER FILE IS DATED 07 JULY 2010.
		MIND	CUR	KENI DISCUVEK FILE IS DAIED U/ JULY 2010.
NEWS	поп	00	C TT1	N Operating Hours Plus Help Desk Availability
NEWS				N Operating Hours Plus Help Desk Availability
NEWS	TIOP I	T TA	we.	Trough Danner and Mews Trains

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:45:57 ON 10 SEP 2010

=> file hcaplus COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
1.32 1.32

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 09:49:11 ON 10 SEP 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Sep 2010 VOL 153 ISS 12 FILE LAST UPDATED: 9 Sep 2010 (20100909/ED) REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (noncrosslinked or non-crosslinked or non (2a) cross (2a) linked) (5a) gelatin and (crosslinked or cross (2a) linked or cross-linked) (5a) gelatin

1329 NONCROSSLINKED
181495 NON
39 NONS
1181525 NON
(NON OR NONS)
131318 CROSSLINKED
1093 NON-CROSSLINKED
(NON (W) CROSSLINKED)
1181495 NON
33 MONS

```
1181525 NON
                (NON OR NONS)
       639239 CROSS
        25354 CROSSES
       660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
        346012 LINKED
                (LINKED OR LINKEDS)
        79322 GELATIN
        39507 GELATINS
        94998 GELATIN
                (GELATIN OR GELATINS)
            18 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED
               ) (5A) GELATIN
        131318 CROSSLINKED
       639239 CROSS
        25354 CROSSES
        660869 CROSS
                 (CROSS OR CROSSES)
        346012 LINKED
             1 LINKEDS
        346012 LINKED
                (LINKED OR LINKEDS)
       639239 CROSS
         25354 CROSSES
       660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
            1 LINKEDS
       346012 LINKED
                (LINKED OR LINKEDS)
        32550 CROSS-LINKED
                (CROSS(W)LINKED)
        79322 GELATIN
        39507 GELATINS
        94998 GELATIN
                 (GELATIN OR GELATINS)
          1526 (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (5A) GELATIN
            16 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED
               ) (5A) GELATIN AND (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LI
               NKED) (5A) GELATIN
=> s (noncrosslinked or non-crosslinked or non (2a) cross (2a) linked) (p)
(crosslinked or cross (2a) linked or cross-linked) (p) gelatin
          1329 NONCROSSLINKED
       1181495 NON
           39 NONS
       1181525 NON
                 (NON OR NONS)
        131318 CROSSLINKED
          1093 NON-CROSSLINKED
                 (NON(W)CROSSLINKED)
       1181495 NON
           39 NONS
       1181525 NON
                (NON OR NONS)
       639239 CROSS
        25354 CROSSES
```

=>

```
660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
            1 LINKEDS
        346012 LINKED
                (LINKED OR LINKEDS)
       131318 CROSSLINKED
       639239 CROSS
         25354 CROSSES
       660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
            1 LINKEDS
        346012 LINKED
                (LINKED OR LINKEDS)
       639239 CROSS
        25354 CROSSES
       660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
            1 LINKEDS
        346012 LINKED
                (LINKED OR LINKEDS)
        32550 CROSS-LINKED
                (CROSS(W)LINKED)
        79322 GELATIN
         39507 GELATINS
        94998 GELATIN
                (GELATIN OR GELATINS)
            41 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED
              ) (P) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P)
               GELATIN
=> s (noncrosslinked or non-crosslinked or non (2a) cross (2a) linked) (p)
(crosslinked or cross (2a) linked or cross-linked) (p) gelatin (p) mixture
         1329 NONCROSSLINKED
       1181495 NON
           39 NONS
       1181525 NON
                (NON OR NONS)
        131318 CROSSLINKED
          1093 NON-CROSSLINKED
                (NON(W)CROSSLINKED)
       1181495 NON
           39 NONS
       1181525 NON
                (NON OR NONS)
       639239 CROSS
        25354 CROSSES
       660869 CROSS
                 (CROSS OR CROSSES)
        346012 LINKED
        346012 LINKED
                 (LINKED OR LINKEDS)
       131318 CROSSLINKED
       639239 CROSS
         25354 CROSSES
       660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
            1 LINKEDS
```

L2

```
346012 LINKED
                (LINKED OR LINKEDS)
       639239 CROSS
        25354 CROSSES
        660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
        346012 LINKED
                (LINKED OR LINKEDS)
        32550 CROSS-LINKED
                (CROSS(W)LINKED)
        79322 GELATIN
        39507 GELATINS
        94998 GELATIN
                (GELATIN OR GELATINS)
        124604 MIXTURE
        157674 MIXTURES
       275234 MIXTURE
                (MIXTURE OR MIXTURES)
       1645286 MIXT
       604632 MIXTS
       2029245 MIXT
                (MIXT OR MIXTS)
       2122398 MIXTURE
                (MIXTURE OR MIXT)
             7 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED
               ) (P) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P)
              GELATIN (P) MIXTURE
=> d 13 ibib kwic 1-
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y
L3 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:
                        2010:423421 HCAPLUS
                        Protein-based films cross-linked with
TITLE:
                        1-ethyl-3-(3-dimethylamino-propyl) carbodiimide
                        hydrochloride (EDC): effects of the cross-linker and
                        film composition on the permeation rate of
                        p-hydroxyacetanilide as a model drug
AUTHOR(S):
                        Cristiano, Claudia M. Z.; Favad, Samira J.; Porto,
                        Ledilege C.; Soldi, Valdir
CORPORATE SOURCE:
                        Grupo de Estudos em Materiais Polimericos (POLIMAT).
                        Departamento de Quimica, Universidade Federal de Santa
                        Catarina, Florianopolis, 88040-900, Brazil
```

Sociedade Brasileira de Ouimica DOCUMENT TYPE: Journal LANGUAGE: English REFERENCE COUNT: THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS 46 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CODEN: JOCSET; ISSN: 0103-5053

21(2), 340-348

Journal of the Brazilian Chemical Society (2010),

SOURCE:

PUBLISHER:

Cross-linked films of gelatin (Gel), casein (Cas) and their (1:1, m/m) mixt. (Gel/Cas) were studied in terms of their thermal, morphol. and water absorption properties and the permeation profile of p-hydroxyacetanilide (p-HAA). . 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) were 90.6% for Gel films and approx. 70% for Cas and Gel/Cas films. The totally sol. non cross-linked films achieved only 21 - 22% of soly. after crosslinking with EDC. Despite the high

crosslinking degree, the swelling of. . . detd. for Gel/Cas and Cas films. The permeation rate of p-HAA followed the order Gel > Gel/Cas .simeq. Cas for cross-linked films, which is consistent with the Gel film showing a greater swelling than the other two

systems studied. Lower permeation. .

ACCESSION NUMBER: 2006:726846 HCAPLUS

DOCUMENT NUMBER: 145:334442

TITLE: Some physical properties of crosslinked

gelatin-maltodextrin hydrogels AUTHOR(S):

L3 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN

Nickerson, M. T.; Paulson, A. T.; Wagar, E.; Farnworth, R.; Hodge, S. M.; Rousseau, D.

CORPORATE SOURCE: Department of Food Science and Technology, Dalhousie

University, Halifax, NS, B3J 2X4, Can. SOURCE: Food Hydrocolloids (2006), 20(7), 1072-1079

CODEN: FOHYES; ISSN: 0268-005X PUBLISHER . Elsevier Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

OS.CITING REF COUNT: THERE ARE 11 CAPLUS RECORDS THAT CITE THIS 11

RECORD (11 CITINGS)

REFERENCE COUNT: THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD, ALL CITATIONS AVAILABLE IN THE RE FORMAT

The phys. properties and morphol. of phase-sepd. gelatin -maltodextrin (MD) systems, cross-linked by

non-toxic, biocompatible fixatives, were investigated as a

function of pH (3, 5 or 7) and MD concn. (0-12% wt./wt.), at a const.

gelatin concn. (10% wt./wt.). Gelatin was cross

-linked by sodium tripolyphosphate (TPP), genipin (GP), a GP/TPP mixt. or by glutaraldehyde (used as a std.). Confocal laser

scanning microscopy of all mixed gels at pH 3 revealed the. . . except in the presence of TPP. Phase sepn. was likely inhibited by reduced network elasticity, increased entropic contribution of the mixt.

and minimal fixative-polymer interaction at this pH. Hydrogels under these conditions were weaker (i.e., lower elastic modulus) and swelled more. . . pH 7, phase sepn. was evident, where numerous MD inclusions

of various diams. (<50 .mu.m) became kinetically trapped within the gelatin-continuous network. In general, the extent of phase sepn.

increased as MD concn. increased. Overall, GP crosslinked networks were strongest at pH 7, whereas TPP fixation gave

the strongest gels at low pH. The addn. of TPP to GP crosslinked hydrogels lead to a large increase in elastic modulus, esp.

near the isoelec. point of gelatin (.apprx.pH 7-9). By

controlling compn., pH and crosslinker, tailored hydrogel morphologies and phys. properties were obtained.

L3 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN

2004:905601 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 141:355427

TITLE: Hemoactive compositions containing polymers Reich, Cary J.; Osawa, A. Edward; Tran, Helen INVENTOR(S): Fusion Medical Technologies, Inc., USA; Baxter PATENT ASSIGNEE(S): International Inc.; Baxter Healthcare S.A.

U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 553,969. SOURCE:

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7 PATENT INFORMATION:

PATENT NO.	KIND	DATE	API	PLICATION NO		DATE
US 20040214770	A1	20041028	US	2004-761922		20040120
US 7320962 US 6066325	B2 A	20080122	110	1998-32370		19980227
US 20020042378	A1	20000323		1999-330315		19990227
US 6706690	B2	20040316	0.0	1000 000010		15550010
US 20020193448	A1	20021219	US	2000-553969		20000421
JP 2006231090	A	20060907		2006-157904		20060606
JP 2009256391	A	20091105		2009-187571		20090812
JP 2010148922	A	20100708		2010-68924		20100324
PRIORITY APPLN. INFO.:				1996-704852 1997-50437P		19960827 19970618
				1997-903674		19970618
				1998-32370		19980227
				1999-330315	A2	19990610
			US	2000-553969	A2	20000421
				1998-511970		19970814
			JP	2001-502866	A3	20000609

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD OS.CITING REF COUNT:

(9 CITINGS) REFERENCE COUNT: THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Dried hemoactive materials comprise both a crosslinked biol. compatible polymer and a noncrosslinked biol. compatible polymer. The crosslinked polymer is selected to form a hydrogel when exposed to blood. The non-crosslinked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the crosslinked polymer will be present in a particulate or fragmented form. The materials are

particularly suitable for hemostasis and drug delivery. . . activated clotting time (ACT) of the animal to approx. 3-5-fold its baseline value. A piece of the lyophilized composite material, cross-

linked gelatin particles and PEG, was applied to the

lesion with compression for 2 min. After compression was removed, no bleeding was. . . 1 min. After compression was removed, no further bleeding was obsd. and the lesion appeared to be sealed with a mixt. of clotted blood and the applied composite material.

L3 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN 2000:900474 HCAPLUS

ACCESSION NUMBER: DOCUMENT NUMBER:

134:46867

TITLE:

Hemoactive compositions and methods for their manufacture and use

Reich, Cary J.; Osawa, A. Edward; Tran, Helen INVENTOR(S): Fusion Medical Technologies, Inc., USA PATENT ASSIGNEE(S):

SOURCE:

PCT Int. Appl., 26 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7 PATENT INFORMATION:

PAT	ENT	NO.			KIN	D	DATE			APPL	ICAT:	ION I	. OP		D	ATE	
						-											
WO	2000	0765	33		A1		2000	1221		WO 2	000-1	JS15	998		2	0000	609
	W:	JP															
	RW:	AT, PT,		CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,

```
US 20020042378 A1 20020411 US 1999-330315 19990610
    US 6706690
                       B2 20040316
A1 20020313 EP 2000-942742
    EP 1185288
                                                                20000609
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE. FI
    JP 2003501215
JP 2010148922
                        T
                            20030114
                                         JP 2001-502866
                                                               20000609
                       A
                             20100708
                                          JP 2010-68924
                                                               20100324
PRIORITY APPLN. INFO.:
                                          US 1999-330315
                                                            A 19990610
                                          JP 2001-502866
                                                            A3 20000609
                                          WO 2000-US15998
                                                            W 20000609
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
                             THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
OS.CITING REF COUNT: 2
                             (2 CITINGS)
REFERENCE COUNT:
                             THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                             RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB Dried hemoactive materials comprise both a crosslinked biol.
    compatible polymer and a non-crosslinked biol.
    compatible polymer. The crosslinked polymer is selected to form
    a hydrogel when exposed to blood. The non-crosslinked
    polymer is chosen to solubilize relatively rapidly when exposed to blood.
    The non-crosslinked polymer serves as a binder for
    holding the materials in desired geometries, such as sheets, pellets,
    plugs, or the like. Usually, the crosslinked polymer will be
    present in a particulate or fragmented form. The materials are
```

particularly suitable for hemostasis and drug delivery. Examples are given for prodn. of uncrosslinked gelatin powder, prodn. of

uncrosslinked biopolymer in sheet form, and used of lyophilized composite

lyophilized composite mixt. of crosslinked and ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN

material as a hemostatic. ACCESSION NUMBER: 1998:570222 HCAPLUS

DOCUMENT NUMBER: 129:293822

ORIGINAL REFERENCE NO.: 129:59855a,59858a TITLE: .beta.-Glucuronidase activity following complex

coacervation and spray drying microencapsulation

AUTHOR(S): Burgess, D. J.; Ponsart, S.

CORPORATE SOURCE: Dep. Pharmaceutical Sciences, School Pharmacy, University Connecticut, Storrs, CT, 06269, USA SOURCE:

Journal of Microencapsulation (1998), 15(5), 569-579

CODEN: JOMIEF; ISSN: 0265-2048

PUBLISHER: Tavlor & Francis Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS

RECORD (10 CITINGS)

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

. . . controlled release of an active protein drug. AB

.beta.-Glucuronidase was selected as a model protein and a combination of complex coacervation (gelatin/sodium alginate, gelatin /acacia and albumin/acacia) and spray drying was investigated. Coacervates were either spray dried or glutaraldehyde crosslinked to form microcapsules. Polyvinylpyrrolidone (PVP) and polyethylene glycol were investigated as potential coacervate enhancers and stabilizers. .beta.-Glucuronidase/polymer mixts. were spray dried to det. any polymer protective effects on protein activity. A BUCHI 190 Spray Drier was used, .beta.-glucuronidase activity was detd. using a Sigma Kit and microcapsule particle size was measured by Accusizer anal. (light blockage). All non-crosslinked coacervates investigated, with the exceptions of albumin/acacia and albumin/acacia/.beta.-glucuronidase/PVP, were unsuitable for spray drying

as they rapidly phase sepd. and. . . activities of approx. 30% and 68% when spray dried alone and with albumin, resp., and of 18% in albumin/acacia microcapsules crosslinked with glutaraldehyde. Microcapsule particle size was affected by coacervation pH, additives and spray drying. In vitro .beta.-qlucuronidase release was biphasic, . . .

L3 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:599526 HCAPLUS DOCUMENT NUMBER: 121:199526

ORIGINAL REFERENCE NO.: 121:36167a,36170a

TITLE: Preparation of gelatin carriers for immobilized

enzymes

INVENTOR(S): Yamamoto, Yoshe

PATENT ASSIGNEE(S): Japan Vilene Co Ltd, Japan SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

DOCUMENT TYPE Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05308969	A	19931122	JP 1992-146177	19920513
PRIORITY APPLN. INFO.:			JP 1992-146177	19920513
3.5		and a sile of a	annoused as as assessed	

AB An enzyme carrier is prepd. which is comprised of reinforced

gelatin gel that contains enzyme and the gel is further covered

with a crosslinked gelatin shell. The carrier is

prepd. by gelation of a mixt. of gelatin colloid

soln., enzymes, and a substance for reinforcement, followed by crosslinking the outer layer of the gel. The prepn. protects the enzyme

activities reside in the non-crosslinked gel by

crosslinked shell and thus ensures repetitive use. Prepn. of the

glucoamylase-contg. gelatin carrier was shown.

L3 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1992:598599 HCAPLUS
DOCUMENT NUMBER: 117:198599

ORIGINAL REFERENCE NO.: 117:34153a,34156a

TITLE: A biologically derived medical adhesive containing collagen or gelatin and its uses

INVENTOR(S): Bowyer, Barry L.; Robin, Jeffrey; Terry, Richard N.;

Garg, Atul K.

PATENT ASSIGNEE(S): Bausch and Lomb Inc., USA SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA:	TENT NO			KIND	DATE	APPLICATION NO.	DATE
WO	9213578			A1		WO 1991-US9638	
	W: AU	J. BB.	BG.	BR, CA	. CS. FI.	HU, JP, KP, KR, LK,	MG, MW, NO, PL,
		, SD,					
	RW: A	r, BE,	CH,	DE, DK	, ES, FR,	GB, GR, IT, LU, MC,	NL, SE
CA	2103728	3		A1	19920812	CA 1991-2103728	19911219
AU	9212498	3		A	19920907	AU 1992-12498	19911219
	652808			B2	19940908		
EP	563331			A1	19931006	EP 1992-904917	19911219
	R: A	Γ, BE,	CH,	DE, DK	, ES, FR,	GB, GR, IT, LI, LU,	MC, NL, SE

```
19930810
     NO 9302838
                      A 19930810
                                           NO 1993-2838
                                            NO 1993-2838 19930810
US 1991-653602 A 19910211
WO 1991-US9638 A 19911219
PRIORITY APPLN. INFO.:
OS.CITING REF COUNT: 2
                             THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
                               (2 CITINGS)
REFERENCE COUNT:
                        2
                               THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
   An adhesive compn. suited for surgical applications comprises an ag. soln.
    of collagen or gelatin which has a melt index temp. of
    33-60.degree, achieved by mixing blends of thermally crosslinked
    and non-crosslinked biopolymers. The adhesive also
    contains an antibiotic. A portion of 10% by wt. porcine scleral collagen
    was dried and heated to 145.degree. for 60 min to produce densely
    crosslinked material. A sec. portion was similarly treated for 15
    min at 145.degree. and served as a noncrosslinked sample. A
    mixt. comprising 5% of noncrosslinked and 95%
    crosslinked material was dild. to various solid concns. (12.5, 15,
    20, and 30% collagen) to obtain compns. with different bonding strengths.
=> s (noncrosslinked or non-crosslinked or non (2a) cross (2a) linked) (p) gelatin
and (swollen or colloid or hydrocolloid or colloidal) (5a) (crosslinked or cross
(2a) linked or cross-linked) (p) gelatin
         1329 NONCROSSLINKED
       1181495 NON
           39 NONS
       1181525 NON
                (NON OR NONS)
        131318 CROSSLINKED
          1093 NON-CROSSLINKED
                (NON(W)CROSSLINKED)
       1181495 NON
           39 NONS
       1181525 NON
                (NON OR NONS)
       639239 CROSS
        25354 CROSSES
       660869 CROSS
                 (CROSS OR CROSSES)
        346012 LINKED
            1 LINKEDS
        346012 LINKED
                (LINKED OR LINKEDS)
        79322 GELATIN
        39507 GELATINS
        94998 GELATIN
                 (GELATIN OR GELATINS)
            50 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED
               ) (P) GELATIN
         21765 SWOLLEN
         58965 COLLOID
         59920 COLLOIDS
         94759 COLLOID
                 (COLLOID OR COLLOIDS)
          2068 HYDROCOLLOID
          2588 HYDROCOLLOIDS
          3350 HYDROCOLLOID
                (HYDROCOLLOID OR HYDROCOLLOIDS)
        146218 COLLOIDAL
            32 COLLOIDALS
        146231 COLLOIDAL
                 (COLLOIDAL OR COLLOIDALS)
```

```
131318 CROSSLINKED
        639239 CROSS
         25354 CROSSES
        660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
             1 LINKEDS
        346012 LINKED
                (LINKED OR LINKEDS)
       639239 CROSS
         25354 CROSSES
        660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
            1 LINKEDS
        346012 LINKED
                (LINKED OR LINKEDS)
        32550 CROSS-LINKED
                (CROSS(W)LINKED)
        79322 GELATIN
         39507 GELATINS
        94998 GELATIN
                 (GELATIN OR GELATINS)
            29 (SWOLLEN OR COLLOID OR HYDROCOLLOID OR COLLOIDAL) (5A) (CROSSLI
              NKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN
            0 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED
               ) (P) GELATIN AND (SWOLLEN OR COLLOID OR HYDROCOLLOID OR COLLOI
               DAL) (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED)
               (P) GELATIN
=> s (noncrosslinked or non-crosslinked or non (2a) cross (2a) linked) (p) gelatin
and (gel or gelled) (5a) (crosslinked or cross (2a) linked or cross-linked) (p)
gelatin
          1329 NONCROSSLINKED
       1181495 NON
           39 NONS
       1181525 NON
                (NON OR NONS)
        131318 CROSSLINKED
          1093 NON-CROSSLINKED
                (NON(W)CROSSLINKED)
       1181495 NON
           39 NONS
       1181525 NON
                 (NON OR NONS)
       639239 CROSS
        25354 CROSSES
        660869 CROSS
                 (CROSS OR CROSSES)
        346012 LINKED
            1 LINKEDS
        346012 LINKED
                 (LINKED OR LINKEDS)
         79322 GELATIN
        39507 GELATINS
        94998 GELATIN
                 (GELATIN OR GELATINS)
            50 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED
              ) (P) GELATIN
       605094 GEL
        126693 GELS
       654793 GEL
```

L.4

```
(GEL OR GELS)
         11754 GELLED
        131318 CROSSLINKED
       639239 CROSS
         25354 CROSSES
        660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
             1 LINKEDS
        346012 LINKED
                (LINKED OR LINKEDS)
        639239 CROSS
        25354 CROSSES
        660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
            1 LINKEDS
        346012 LINKED
                (LINKED OR LINKEDS)
        32550 CROSS-LINKED
                (CROSS(W)LINKED)
         79322 GELATIN
         39507 GELATINS
        94998 GELATIN
                (GELATIN OR GELATINS)
           178 (GEL OR GELLED) (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS
              -LINKED) (P) GELATIN
             4 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED
              ) (P) GELATIN AND (GEL OR GELLED) (5A) (CROSSLINKED OR CROSS
               (2A) LINKED OR CROSS-LINKED) (P) GELATIN
=> d 15 ibib 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):v
L5 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:
                        2010:423421 HCAPLUS
TITLE:
                        Protein-based films cross-linked with
                         1-ethyl-3-(3-dimethylamino-propyl) carbodiimide
                        hydrochloride (EDC): effects of the cross-linker and
                        film composition on the permeation rate of
                        p-hydroxyacetanilide as a model drug
AUTHOR(S):
                        Cristiano, Claudia M. Z.; Favad, Samira J.; Porto,
                         Ledilege C.; Soldi, Valdir
CORPORATE SOURCE:
                        Grupo de Estudos em Materiais Polimericos (POLIMAT),
                        Departamento de Quimica, Universidade Federal de Santa
                        Catarina, Florianopolis, 88040-900, Brazil
SOURCE:
                        Journal of the Brazilian Chemical Society (2010),
                        21(2), 340-348
                        CODEN: JOCSET: ISSN: 0103-5053
                        Sociedade Brasileira de Quimica
PUBLISHER:
DOCUMENT TYPE:
                        Journal
LANGUAGE:
                        English
                              THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS
REFERENCE COUNT:
                        46
                              RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

ACCESSION NUMBER: 2005:481790 HCAPLUS
DOCUMENT NUMBER: 144:177204
TITLE: Bio-sorption of acidic gelatine hydro-gels implanted in the back tissues of Fisher's rats

AUTHOR(S): Taira, M.; Furuuchi, H.; Saitoh, S.; Sugiyama, Y.;

L5 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN

Sekiyama, S.; Araki, Y.; Tabata, Y.

CORPORATE SOURCE: Department of Dental Materials Science and Technology,
Iwate Medical University School of Dentistry, Iwate,

Japan

SOURCE: Journal of Oral Rehabilitation (2005), 32(5), 382-387

CODEN: JORHBY; ISSN: 0305-182X PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: Journal English

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:343349 HCAPLUS

DOCUMENT NUMBER: 133:168312

TITLE: In vivo and in vitro release of lysozyme from

cross-linked gelatin hydrogels: a model system for the delivery of antibacterial proteins from prosthetic

heart valves

AUTHOR(S): Kuijpers, A. J.; van Wachem, , P. B.; van Luyn, , M. J. A.; Engbers, G. H. M.; Krijgsveld, J.; Zaat, S. A.

J.; Dankert, J.; Feijen, J.

CORPORATE SOURCE: Institute of Biomedical Technology, Department of

Chemical Technology, University of Twente, Enschede, 7500 AE, Neth.

SOURCE: Journal of Controlled Release (2000), 67(2-3), 323-336

CODEN: JCREEC; ISSN: 0168-3659

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD

(9 CITINGS)
REFERENCE COUNT: 22 THERE ARE 2:

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:599526 HCAPLUS DOCUMENT NUMBER: 121:199526

DOCUMENT NUMBER: 121:199526 ORIGINAL REFERENCE NO.: 121:36167a,36170a

TITLE: Preparation of gelatin carriers for immobilized

enzvmes

INVENTOR(S): Yamamoto, Yoshe

PATENT ASSIGNEE(S): Japan Vilene Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

JP 05308969 A 19931122 JP 1992-146177 19920513
PRIORITY APPLIN. INFO.: JP 1992-146177 19920513

L5 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:599526 HCAPLUS

DOCUMENT NUMBER: 121:199526

ORIGINAL REFERENCE NO.: 121:36167a,36170a

TITLE: Preparation of gelatin carriers for immobilized

enzymes
INVENTOR(S): Yamamoto, Yoshe

PATENT ASSIGNEE(S): Japan Vilene Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF
DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05308969	A	19931122	JP 1992-146177	19920513
PRIORITY APPLN. INFO.:			JP 1992-146177	19920513
AB An enzyme carrier	is prepd	. which is	comprised of reinforced	

gelatin gel that contains enzyme and the gel is further covered with a crosslinked gelatin shell. The carrier is prepd. by gelation of a mixt. of gelatin colloid soln., enzymes, and a substance for reinforcement, followed by crosslinking the outer layer of the gel. The prepn. protects the enzyme activities reside in the non-crosslinked gel by

crosslinked shell and thus ensures repetitive use. Prepn. of the glucoamylase-contq. gelatin carrier was shown.

=> d his full

(FILE 'HOME' ENTERED AT 09:45:57 ON 10 SEP 2010)

FILE 'HCAPLUS' ENTERED AT 09:49:11 ON 10 SEP 2010

- L1 16 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (5A) GELATIN AND (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (5A) GELATIN AND (CROSSLINKED OR CROSS-LINKED) (5A) GELATIN
- .2 41 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN
 - 7 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN (P) MIXTURE D L3 IBIE NUIC 1-D
- L4 0 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON
 (2A) CROSS (2A) LINKED) (P) GELATIN AND (SWOLLEN OR COLLOID
 OR HYDROCOLLOID OR COLLOIDAL) (5A) (CROSSLINKED OR CROSS (2A)
 LINKED OR CROSS-LINKED) (P) GELATIN
- L5 4 SEA ABB=ON PLU=ON (NONCRÖSSLINKED OR NON-CROSSLINKED OR NON
 (2A) CROSS (2A) LINKED) (P) GELATIN AND (GEL OR GELLED) (5A)
 (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN
 D L5 IBIB 1-
 - D L5 4 IBIB KWIC

FILE HOME

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Sep 2010 VOL 153 ISS 12 FILE LAST UPDATED: 9 Sep 2010 (20100909/ED) REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (noncrosslinked or non-crosslinked or non (2a) cross (2a) linked) (p) gelatin and (fragment or fragmented or disrupted or particle or particulate) (p) (gel or gelled) (5a) (crosslinked or cross (2a) linked or cross-linked) (p) gelatin

1329 NONCROSSLINKED 1181495 NON 39 NONS 1181525 NON (NON OR NONS) 131318 CROSSLINKED 1093 NON-CROSSLINKED (NON(W)CROSSLINKED) 1181495 NON 39 NONS 1181525 NON (NON OR NONS) 639239 CROSS 25354 CROSSES 660869 CROSS (CROSS OR CROSSES) 346012 LINKED 1 LINKEDS 346012 LINKED (LINKED OR LINKEDS) 79322 GELATIN 39507 GELATINS 94998 GELATIN (GELATIN OR GELATINS) 50 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) GELATIN 241722 FRAGMENT 230941 FRAGMENTS

412778 FRAGMENT (FRAGMENT OR FRAGMENTS) 11212 FRAGMENTED

35774 DISRUPTED 948523 PARTICLE 1002461 PARTICLES

1547396 PARTICLE

(PARTICLE OR PARTICLES)

```
130082 PARTICULATE
        25315 PARTICULATES
        142815 PARTICULATE
                (PARTICULATE OR PARTICULATES)
       605094 GEL
       126693 GELS
       654793 GEL
                (GEL OR GELS)
        11754 GELLED
        131318 CROSSLINKED
       639239 CROSS
        25354 CROSSES
        660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
            1 LINKEDS
        346012 LINKED
                (LINKED OR LINKEDS)
       639239 CROSS
        25354 CROSSES
        660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
            1 LINKEDS
        346012 LINKED
                (LINKED OR LINKEDS)
        32550 CROSS-LINKED
                (CROSS(W)LINKED)
         79322 GELATIN
        39507 GELATINS
        94998 GELATIN
                 (GELATIN OR GELATINS)
            10 (FRAGMENT OR FRAGMENTED OR DISRUPTED OR PARTICLE OR PARTICULATE)
               (P) (GEL OR GELLED) (5A) (CROSSLINKED OR CROSS (2A) LINKED
              OR CROSS-LINKED) (P) GELATIN
            0 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED
              ) (P) GELATIN AND (FRAGMENT OR FRAGMENTED OR DISRUPTED OR PARTIC
               LE OR PARTICULATE) (P) (GEL OR GELLED) (5A) (CROSSLINKED OR
              CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN
=> s (noncrosslinked or non-crosslinked or non (2a) cross (2a) linked) (p) gelatin
and (fragment or fragmented or disrupted or particle or particulate) (p)
(hydrated) (5a) (crosslinked or cross (2a) linked or cross-linked) (p) gelatin
          1329 NONCROSSLINKED
       1181495 NON
           39 NONS
       1181525 NON
                (NON OR NONS)
        131318 CROSSLINKED
          1093 NON-CROSSLINKED
                 (NON(W)CROSSLINKED)
       1181495 NON
           39 NONS
       1181525 NON
                (NON OR NONS)
       639239 CROSS
         25354 CROSSES
       660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
            1 LINKEDS
        346012 LINKED
```

L6

```
(LINKED OR LINKEDS)
  79322 GELATIN
  39507 GELATINS
 94998 GELATIN
         (GELATIN OR GELATINS)
     50 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED
        ) (P) GELATIN
 241722 FRAGMENT
 230941 FRAGMENTS
 412778 FRAGMENT
         (FRAGMENT OR FRAGMENTS)
 11212 FRAGMENTED
 35774 DISRUPTED
948523 PARTICLE
1002461 PARTICLES
1547396 PARTICLE
         (PARTICLE OR PARTICLES)
130082 PARTICULATE
 25315 PARTICULATES
 142815 PARTICULATE
         (PARTICULATE OR PARTICULATES)
  71668 HYDRATED
      1 HYDRATEDS
  71669 HYDRATED
         (HYDRATED OR HYDRATEDS)
 131318 CROSSLINKED
639239 CROSS
  25354 CROSSES
660869 CROSS
         (CROSS OR CROSSES)
 346012 LINKED
     1 LINKEDS
 346012 LINKED
         (LINKED OR LINKEDS)
639239 CROSS
 25354 CROSSES
660869 CROSS
         (CROSS OR CROSSES)
 346012 LINKED
      1 LINKEDS
 346012 LINKED
         (LINKED OR LINKEDS)
 32550 CROSS-LINKED
         (CROSS(W)LINKED)
  79322 GELATIN
  39507 GELATINS
 94998 GELATIN
          (GELATIN OR GELATINS)
      0 (FRAGMENT OR FRAGMENTED OR DISRUPTED OR PARTICLE OR PARTICULATE)
        (P) (HYDRATED) (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROS
        S-LINKED) (P) GELATIN
      0 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED
        ) (P) GELATIN AND (FRAGMENT OR FRAGMENTED OR DISRUPTED OR PARTIC
        LE OR PARTICULATE) (P) (HYDRATED) (5A) (CROSSLINKED OR CROSS
        (2A) LINKED OR CROSS-LINKED) (P) GELATIN
```

>> s (noncrosslinked or non-crosslinked or non (2a) cross (2a) linked) (p) gelatin and (fragment or fragmented or disrupted or particle or particulate) (5a) (crosslinked or cross (2a) linked or cross-linked) (p) gelatin

1329 NONCROSSLINKED

1181495 NON 39 NONS

L7

```
1181525 NON
         (NON OR NONS)
131318 CROSSLINKED
  1093 NON-CROSSLINKED
         (NON(W)CROSSLINKED)
1181495 NON
    39 NONS
1181525 NON
         (NON OR NONS)
639239 CROSS
  25354 CROSSES
660869 CROSS
         (CROSS OR CROSSES)
 346012 LINKED
     1 LINKEDS
 346012 LINKED
         (LINKED OR LINKEDS)
 79322 GELATIN
 39507 GELATINS
 94998 GELATIN
         (GELATIN OR GELATINS)
     50 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED
        ) (P) GELATIN
 241722 FRAGMENT
 230941 FRAGMENTS
 412778 FRAGMENT
         (FRAGMENT OR FRAGMENTS)
  11212 FRAGMENTED
 35774 DISRUPTED
948523 PARTICLE
1002461 PARTICLES
1547396 PARTICLE
         (PARTICLE OR PARTICLES)
130082 PARTICULATE
 25315 PARTICULATES
 142815 PARTICULATE
         (PARTICULATE OR PARTICULATES)
 131318 CROSSLINKED
639239 CROSS
 25354 CROSSES
660869 CROSS
         (CROSS OR CROSSES)
 346012 LINKED
     1 LINKEDS
 346012 LINKED
         (LINKED OR LINKEDS)
639239 CROSS
 25354 CROSSES
 660869 CROSS
          (CROSS OR CROSSES)
 346012 LINKED
 346012 LINKED
          (LINKED OR LINKEDS)
  32550 CROSS-LINKED
          (CROSS(W)LINKED)
  79322 GELATIN
  39507 GELATINS
  94998 GELATIN
          (GELATIN OR GELATINS)
     87 (FRAGMENT OR FRAGMENTED OR DISRUPTED OR PARTICLE OR PARTICULATE)
          (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P)
```

3 (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) GELATIN AND (FRAGMENT OR FRAGMENTED OR DISRUPTED OR PARTIC LE OR PARTICULATE) (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN

=> d 18 ibib kwic 1-

YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):v

L8 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:905601 HCAPLUS

DOCUMENT NUMBER: 141:355427

TITLE:

Hemoactive compositions containing polymers INVENTOR(S): Reich, Cary J.; Osawa, A. Edward; Tran, Helen PATENT ASSIGNEE(S): Fusion Medical Technologies, Inc., USA; Baxter International Inc.; Baxter Healthcare S.A.

SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 553,969.

CODEN: USXXCO Patent

DOCUMENT TYPE: LANGUAGE: English FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040214770 US 7320962	A1 B2	20041028	US 2004-761922	20040120
US 6066325 US 20020042378	A Al	20000523	US 1998-32370 US 1999-330315	19980227 19990610
US 6706690 US 20020193448	B2 A1	20040316 20021219	US 2000-553969	20000421
JP 2006231090 JP 2009256391	A A	20060907 20091105	JP 2006-157904 JP 2009-187571	20060606 20090812
JP 2010148922 PRIORITY APPLN. INFO.:	A	20100708	JP 2010-68924 US 1996-704852 B2	20100324 19960827
				19970618 19970731
				19990610
			JP 1998-511970 A3	20000421 19970814
			JP 2001-502866 A3	20000609

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS.CITING REF COUNT: THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD

(9 CITINGS) REFERENCE COUNT: THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS 65 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Dried hemoactive materials comprise both a crosslinked biol. compatible polymer and a noncrosslinked biol. compatible polymer. The crosslinked polymer is selected to form a hydrogel when exposed to blood. The non-crosslinked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross

-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like.. activated clotting time (ACT) of the animal to approx. 3-5-fold its baseline value. A piece of the lyophilized composite material, cross-linked gelatin particles and

PEG, was applied to the lesion with compression for 2 min. After compression was removed, no bleeding was obsd.. . .

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:47501 HCAPLUS

DOCUMENT NUMBER: 136:107226

TITLE: Agar or gelatin hydrogel matrix particles for skin

cosmetics

INVENTOR(S): Sakai, Shigefumi; Kiba, Atsuyuki; Shigeno, Chitoshi;

Kubo, Hideaki PATENT ASSIGNEE(S): Kao Corporation, Japan

SOURCE: Eur. Pat. Appl., 28 pp.

CODEN: EPXXDW DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

REFERENCE COUNT:

PA	TENT I				DATE	DATE		APPLICATION NO.					DATE				
	11720				A2		2002		EP 2001-114885						20010629		
EP	11720				A3		2002										
	R:	AT,						FR,	GB,	GE	R, IT,	LΙ,	LU,	NL,	SE	, MC,	PT,
				LI,	LV,												
	20020		27		A		2002			JP	2000-	1985	43			20000	630
JP	37560	042			B2		2006	0315									
JP	20020	02022	28		A		2002	0123		JΡ	2000-	1994	01			20000	630
JP	37560	043			B2		2006	0315									
JP	20020	05899	9.0		A		2002	0226		JΡ	2000-	2457	0.8			20000	814
JP	35559	937			B2		2004	0818									
US	20020	00345	525		A1		2002	0321		US	2001-	8925	77			20010	628
JP	20023	15983	38		A		2002	0604		JP	2001-	2410	12			20010	808
JP	34835	543			B2		2004	0106									
US	20090	01553	323		A1		2009	0618		US	2009-	3903	90			20090	220
PRIORIT	Y APPI	LN.	INFO	. :						JP	2000-	1985	43	Z	A	20000	630
										JΡ	2000-	1994	01	I	À.	20000	630
										JP	2000-	2457	0.8	I	À.	20000	814
										JP	2000-	2457	09	7	4	20000	814
										US	2001-	8925	77	E	33	20010	628

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD

(28 CITINGS)

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

A skin cosmetic compn. comprises non-crosslinked

hydrogel particles made of agar or gelatin in which an

oil component is emulsified or dispersed. The oil component is a liq., e.g., polyglyceryl diisostearate, or solid. . .

L8 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1988:556156 HCAPLUS DOCUMENT NUMBER: 109:156156

ORIGINAL REFERENCE NO.: 109:25853a,25856a Optimization of controlled drug release through

TITLE: micropelletization

AUTHOR(S): Das, Sudip K.; Gupta, Bijan K.

Dep. Pharm., Jadavpur Univ., Calcutta, 700032, India CORPORATE SOURCE: Drug Development and Industrial Pharmacy (1988), SOURCE:

14(12), 1673-97 CODEN: DDIPD8; ISSN: 0363-9045

DOCUMENT TYPE: Journal LANGUAGE: English

OS.CITING REF COUNT: THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

AB Micropelletization technique using crosslinked gelatin matrix

was chosen to evaluate its utility in controlled release medications. Trimethoprim, which has a very high soly gradient in. . . selected. Micropellets were formed by the modified spray congealing technique. The effects of exposure of the crosslinking agents to the gelatin matrix of the micropellets on the effectivity as the controlled-release drug delivery system were investigated. The total product yield, content uniformity and the reproducibility of the successive batches were decidedly superior to either the pure drug or the noncrosslinked ones. Particle size distribution varied depending on the content of the crosslinked gelatin in the micropellets. Scanning electron micrographs confirmed the porous surface topog. of the micropellets. The drug release characteristics was suggested.

IT Particle size

(of crosslinked gelatin micropellets, controlled drug release in relation to)

=> d his full

(FILE 'HOME' ENTERED AT 09:45:57 ON 10 SEP 2010)

FILE 'HCAPLUS' ENTERED AT 09:49:11 ON 10 SEP 2010

- L1 16 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON
 (2A) CROSS (2A) LINKED) (5A) GELATIN AND (CROSSLINKED OR CROSS
 (2A) LINKED OR CROSS-LINKED) (5A) GELATIN
- L2 41 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN
- L3 7 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON
 (2A) CROSS (2A) LINKED) (P) (CROSSLINKED OR CROSS (2A) LINKED
 OR CROSS-LINKED) (P) GELATIN (P) MIXTURE
 D L3 IBIB KWIC 1-
- L4 0 SEA ABB-ON PLU-ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON
 (2A) CROSS (2A) LINKED) (P) GELATIN AND (SWOLLEN OR COLLOID
 OR HYDROCOLLOID OR COLLOIDAL) (5A) (CROSSLINKED OR CROSS (2A)
 LINKED OR CROSS-LINKED) (P) GELATIN
- L5 4 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) GELATIN AND (GEL OR GELLED) (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN D L5 IBIB 1D L5 4 IBIB KWIC
- L6 0 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) GELATIN AND (FRACMENT OR FRACMENTED OR DISRUPTED OR PARTICLE OR PARTICULATE) (P) (GEL OR GELLED) (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN
- L7 0 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON(2A) CROSS (2A) LINKED) (P) GELATIN AND (FRAGMENT OR FRAGMENTED
 OR DISRUPTED OR PARTICLE OR PARTICULATE) (P) (HYDRATED) (5A)
 (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P)
 GELATIN
- L8 3 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON
 (2A) CROSS (2A) LINKED) (P) GELATIN AND (FRAGMENT OR FRAGMENTED
 OR DISRUPTED OR PARTICLE OR PARTICULATE) (5A) (CROSSLINKED
 OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN
 D L8 IBIB KWIC 1-

FILE HOME

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Sep 2010 VOL 153 ISS 12 FILE LAST UPDATED: 9 Sep 2010 (20100909/ED) REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13 and polyoxyethylene 57172 POLYOXYETHYLENE 640 POLYOXYETHYLENES 57373 POLYOXYETHYLENE (POLYOXYETHYLENE OR POLYOXYETHYLENES) L9

0 L3 AND POLYOXYETHYLENE

=> s 13 and glucosaminoglycan

234 GLUCOSAMINOGLYCAN 185 GLUCOSAMINOGLYCANS 365 GLUCOSAMINOGLYCAN

(GLUCOSAMINOGLYCAN OR GLUCOSAMINOGLYCANS)

0 L3 AND GLUCOSAMINOGLYCAN

=> s 13 and dextran

43811 DEXTRAN 4501 DEXTRANS 44741 DEXTRAN

142815 PARTICULATE

(DEXTRAN OR DEXTRANS)

0 L3 AND DEXTRAN

=> s (fragment or fragmented or disrupted or particle or particulate) (p) (hydrogel or hydrocolloidal or hydrocolloid or hydrated) (5a) (crosslinked or cross (2a) linked or cross-linked) (p) gelatin

241722 FRAGMENT 230941 FRAGMENTS 412778 FRAGMENT (FRAGMENT OR FRAGMENTS) 11212 FRAGMENTED 35774 DISRUPTED 948523 PARTICLE 1002461 PARTICLES 1547396 PARTICLE (PARTICLE OR PARTICLES) 130082 PARTICULATE 25315 PARTICULATES

```
(PARTICULATE OR PARTICULATES)
         28479 HYDROGEL
         29151 HYDROGELS
         36804 HYDROGEL
                 (HYDROGEL OR HYDROGELS)
           95 HYDROCOLLOIDAL
          2068 HYDROCOLLOID
          2588 HYDROCOLLOIDS
         3350 HYDROCOLLOID
                (HYDROCOLLOID OR HYDROCOLLOIDS)
         71668 HYDRATED
             1 HYDRATEDS
         71669 HYDRATED
                 (HYDRATED OR HYDRATEDS)
        131318 CROSSLINKED
       639239 CROSS
         25354 CROSSES
       660869 CROSS
                (CROSS OR CROSSES)
        346012 LINKED
        346012 LINKED
                (LINKED OR LINKEDS)
       639239 CROSS
        25354 CROSSES
       660869 CROSS
                 (CROSS OR CROSSES)
        346012 LINKED
             1 LINKEDS
        346012 LINKED
                (LINKED OR LINKEDS)
        32550 CROSS-LINKED
                (CROSS(W)LINKED)
        79322 GELATIN
        39507 GELATINS
        94998 GELATIN
                (GELATIN OR GELATINS)
             9 (FRAGMENT OR FRAGMENTED OR DISRUPTED OR PARTICLE OR PARTICULATE)
               (P) (HYDROGEL OR HYDROCOLLOIDAL OR HYDROCOLLOID OR HYDRATED)
               (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P)
               GELATIN
=> s 112 and (dextran or glycosaminoglycan or polysaccharide)
         43811 DEXTRAN
         4501 DEXTRANS
         44741 DEXTRAN
                 (DEXTRAN OR DEXTRANS)
        12858 GLYCOSAMINOGLYCAN
        16234 GLYCOSAMINOGLYCANS
         19615 GLYCOSAMINOGLYCAN
                 (GLYCOSAMINOGLYCAN OR GLYCOSAMINOGLYCANS)
        76706 POLYSACCHARIDE
        97552 POLYSACCHARIDES
        122197 POLYSACCHARIDE
                 (POLYSACCHARIDE OR POLYSACCHARIDES)
             3 L12 AND (DEXTRAN OR GLYCOSAMINOGLYCAN OR POLYSACCHARIDE)
=> d 113 ibib kwic 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):v
```

L13 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:615598 HCAPLUS

DOCUMENT NUMBER: 150:558360

TITLE: Cryopreservation of cells using cross-linked bioactive

hydrogel matrix particles

INVENTOR(S): Klann, Richard C.; Lamberti, Francis V.; Hill, Ronald

PATENT ASSIGNEE(S): Pioneer Surgical Orthobiologics, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 29pp.

CODEN: USXXCO DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

	PATENT NO.					KIND DATE		APPLICATION NO.									
US	20090130756 2009067601			A1 20090521			US 2008-274765 WO 2008-US84196										
	W:	ΑE,	AG,	AL,	AM,	AO,	AT,	AU,	AZ,	BA,	BB,	BG,	BH,	BR,	BW,	BY,	BZ,
		CA,	CH,	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DO,	DZ,	EC,	EE,	EG,	ES,
		FI,	GB,	GD,	GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,
		KG,	KM,	KN,	KP,	KR,	KZ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LY,	MA,	MD,
		ME,	MG,	MK,	MN,	MW,	MX,	MY,	MZ,	NA,	NG,	NI,	NO,	ΝZ,	OM,	PG,	PH,
		PL,	PΤ,	RO,	RS,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	ST,	SV,	SY,	ΤJ,
		TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	ZA,	ZM,	ZW		
	RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HR,	HU,
		ΙE,	IS,	IT,	LT,	LU,	LV,	MC,	MT,	NL,	NO,	PL,	PT,	RO,	SE,	SI,	SK,
		TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,
							LS,				SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,
		AM,	ΑZ,				MD,										
EP 2222159					A1		2010	0901		EP 2	-800	8529	24		2	0081	120
	R:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HR,	HU,
		ΙE,	IS,	ΙT,	LI,	LT,	LU,	LV,	MC,	MT,	NL,	NO,	PL,	PΤ,	RO,	SE,	SI,
		SK,	TR,	AL,	BA,	MK,	RS										
PRIORIT	Y APP	LN.	INFO	. :						US 2							
										WO 2	-800	US84	196	1	W 2	0081	120

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IT Aggrecans

Collagens Decorins

Entactin

Fibrillins

Fibulins

Gelatins

Glycoproteins Keratins

Laminins

Peptides

Polysaccharides

Proteins RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(cryopreservation of cells using cross-linked

bioactive hydrogel matrix particles)

Polysaccharides

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(sulfated; cryopreservation of cells using cross-linked bioactive hydrogel matrix particles)

1398-61-4, Chitin 9000-07-1, Carrageenan 9004-34-6, Cellulose, biological studies 9004-54-0, Dextran, biological studies 9004-61-9, Hyaluronic acid 9005-25-8, Starch, biological studies

9005-32-7, Alginic acid 9005-49-6, Heparin, biological studies 9005-79-2, Glycogen, biological studies 9005-82-7, Amylose 9007-28-7, Chondroitin sulfate 9012-36-6, Agarose 9012-76-4, Chitosan 9037-22-3, Amylopectin 9042-14-2, Dextran sulfate 9050-30-0 9056-36-4, Keratan sulfate 24967-94-0, Dermatan sulfate 70226-44-7, Heparan 1000410-96-7, Polyglycan RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(Uses) (cryopreservation of cells using cross-linked bioactive hydrogel matrix particles)

L13 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:956472 HCAPLUS

TITLE: Smart membranes from stimuli-sensitive biopolymer

hydrogel

AUTHOR(S): Gopishetty, Venkateshwarlu; Tokarev, Ihor; Minko,

Sergiv Department of Chemistry and Biomolecular Science,

CORPORATE SOURCE:

Clarkson University, Potsdam, NY, 13699-5810, USA SOURCE: Abstracts of Papers, 236th ACS National Meeting,

Philadelphia, PA, United States, August 17-21, 2008 (2008), PMSE-400. American Chemical Society:

Washington, D. C.

CODEN: 69KXO2

DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)

LANGUAGE: English

Responsive biopolymer hydrogel membranes were prepd. by salt-induced phase sepn. of polysaccharide (sodium alginate) and protein (

gelatin). The membranes are biocompatible, biodegradable and were used as a platform for immobilization of metal nanoparticles and

functional proteins. The tunable permeability of the crosslinked

hydrogel membrane was investigated for the diffusion of a water-sol. dye across the membrane. The permeability of the dye mols. was

monitored with a UV-Vis spectrophotometer and was found to be pH

dependent. Incorporation of silver particles inside the

hydrogel membrane was performed by the redn. of silver salt. The presence of silver particles was detected optically via the localized

surface plasmon absorption band. The glucose-sensitivity of the membrane was enabled by chem. immobilization. .

L13 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:344042 HCAPLUS

DOCUMENT NUMBER: 132:352803

TITLE: Fragmented polymeric compositions and methods for

their use

INVENTOR(S): Wallace, Donald G.; Reich, Cary J.; Shargill, Narinder S.; Vega, Felix; Osawa, A. Edward

PATENT ASSIGNEE(S): Fusion Medical Technologies, Inc., USA

SOURCE: U.S., 20 pp., Cont.-in-part of U.S. Ser. No. 903,674.

CODEN: USXXAM

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7 PATENT INFORMATION:

PA:	TENT NO.	KIND	DATE	APPLICATION	NO.	DATE
US	6066325	A	20000523	US 1998-3231	0	19980227
US	20020193448	A1	20021219	US 2000-5539	169	20000421
US	20040214770	A1	20041028	US 2004-7619	22	20040120
US	7320962	B2	20080122			
JP	2006231090	A	20060907	JP 2006-1579	04	20060606

```
US 20080085316 A1 20080410 US 2007-859312 20070921

JP 2009256391 A 20091105 JP 2009-187571 20090812

IITY APPLN. INFO.: US 1996-704852 B2 19960827

US 1997-50437P P 19970618

US 1997-503674 A2 19970731

JP 1998-511970 A3 19970814
PRIORITY APPLN. INFO.:
                                                US 1998-32370
                                                                     A1 19980227
                                                US 1999-330315
                                                                     A2 19990610
                                                US 2000-553969 A2 20000421
US 2001-908464 A2 20010717
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS.CITING REF COUNT:
                          10
                                  THERE ARE 10 CAPLUS RECORDS THAT CITE THIS
                                  RECORD (10 CITINGS)
REFERENCE COUNT:
                           18
                                  THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
                                  RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB Crosslinked hydrogels comprise a variety of biol. and
     non-biol. polymers, such as proteins, polysaccharides, and
     synthetic polymers. Such hydrogels preferably have no free aq. phase and
     may be applied to target sites in a patient's body by extruding the
     hydrogel through an orifice at the target site. Alternatively, the
     hydrogels may be mech. disrupted and used in implantable
     articles, such as breast implants. When used in vivo, the compns. are
     useful for controlled release. . . tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. A
     product was prepd. from gelatin, NaOH and Na periodate to give
     swollen granules which were washed and dried and resuspended in solns.
     contq. Na phosphate. . .
     Polysaccharides, biological studies
     Proteins, general, biological studies
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (fragmented polymeric compns. for implants and drug delivery)
=> s (wound healing) (p) (glycosaminoglycan)
          81106 WOUND
          12781 WOUNDS
          84977 WOUND
                  (WOUND OR WOUNDS)
          52103 HEALING
             39 HEALINGS
          52122 HEALING
                  (HEALING OR HEALINGS)
          32480 WOUND HEALING
                  (WOUND(W) HEALING)
          12858 GLYCOSAMINOGLYCAN
          16234 GLYCOSAMINOGLYCANS
          19615 GLYCOSAMINOGLYCAN
                   (GLYCOSAMINOGLYCAN OR GLYCOSAMINOGLYCANS)
            281 (WOUND HEALING) (P) (GLYCOSAMINOGLYCAN)
L14
=> s (wound healing) (p) (glycosaminoglycan) (gelatin)
MISSING OPERATOR NOGLYCAN) (GELATIN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
=> s (wound healing) (p) (glycosaminoglycan (p)) (gelatin)
MISSING TERM 'P))
The search profile that was entered contains a logical operator
followed immediately by a right parenthesis ')'.
=> s (wound healing) (p) (glycosaminoglycan) (p) (gelatin)
          81106 WOUND
```

```
12781 WOUNDS
         84977 WOUND
                 (WOUND OR WOUNDS)
         52103 HEALING
           39 HEALINGS
         52122 HEALING
                 (HEALING OR HEALINGS)
         32480 WOUND HEALING
                 (WOUND (W) HEALING)
         12858 GLYCOSAMINOGLYCAN
         16234 GLYCOSAMINOGLYCANS
         19615 GLYCOSAMINOGLYCAN
                 (GLYCOSAMINOGLYCAN OR GLYCOSAMINOGLYCANS)
         79322 GELATIN
         39507 GELATINS
         94998 GELATIN
                 (GELATIN OR GELATINS)
             5 (WOUND HEALING) (P) (GLYCOSAMINOGLYCAN) (P) (GELATIN)
=> s 115 and polyoxyethylene
         57172 POLYOXYETHYLENE
          640 POLYOXYETHYLENES
         57373 POLYOXYETHYLENE
                 (POLYOXYETHYLENE OR POLYOXYETHYLENES)
            0 L15 AND POLYOXYETHYLENE
=> d 115 scan
     5 ANSWERS
                 HCAPLUS COPYRIGHT 2010 ACS on STN
IPCI A61L0027-00 [ICM, 4]
IPCR A61L0027-00 [I,C*]; A61L0027-00 [I,A]
    63-7 (Pharmaceuticals)
    Crosslinked glycosaminoglycan composites as artificial organs
    artificial organ glycosaminoglycan collagen gelatin; skin artificial
    hvaluronate atelocollagen
    Gelatins, compounds
    RL: BIOL (Biological study)
        (composites with crosslinked glycosaminoglycans, for artificial organs)
     Surgical dressings and goods
       (crosslinked glycosaminoglycan composites as)
     Organ
     Skin
        (artificial, crosslinked glycosaminoglycan composites as)
    Collagens, compounds
     RL: BIOL (Biological study)
        (atelo-, composites with crosslinked glycosaminoglycans, for artificial
       organs)
    Mucopolysaccharides, compounds
     RL: BIOL (Biological study)
        (glycosaminoglycans, composites with collagens or gelatins, for
       artificial skin)
    9005-49-6DP, composites with collagens or gelatins 9067-32-7DP,
     composites with collagens or gelatins 12678-07-8DP, composites with
     collagens or gelatins 24967-94-ODP, composites with collagens or
     gelatins 25322-46-7DP, composites with collagens or gelatins
     39455-18-ODP, composites with collagens or gelating
     RL: PREP (Preparation)
        (prepn. of, for artificial organ)
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4
     5 ANSWERS HCAPLUS COPYRIGHT 2010 ACS on STN
```

1.15

L16

CC

1.15

- CC 63-7 (Pharmaceuticals)
- TI Vocal Fold Tissue Repair in Vivo Using a Synthetic Extracellular Matrix
- ST synthetic extracellular matrix vocal fold tissue repair Carbylan GSX
- IT Elasticity
 - (Carbylan-SX and Carbylan-GSX improved tissue elasticity in rabbit vocal fold wound healing model)
- IT Viscosity
 - (Carbylan-SX and Carbylan-GSX improved tissue viscosity in rabbit vocal fold wound healing model)
- IT Transforming growth factor .beta.
 - RL: BSU (Biological study, unclassified); BJOL (Biological study) (TGF.beta.1; expression level of transforming growth factor .beta.1 mRNA was not affected by Carbylan-SX and Carbylan-GSX in rabbit vocal fold wound healing model)
- IT Extracellular matrix
 - (artificial; synthetic extracellular matrix Carbylan-GSX exhibited optimal biol. and biomech. properties and promoted wound repair and tissue regeneration in rabbit vocal fold wound healing model)
- IT Fibromodulins
 - RL: BSU (Biological study, unclassified); BIOL (Biological study) (expression level of fibromodulin mRNA was not affected by Carbylan-SX and Carbylan-GSX in rabbit vocal fold wound healing model)
- IT Fibronectins
 - RL: BSU (Biological study, unclassified); BIOL (Biological study) (expression level of fibronectin mRNA was not affected by Carbylan-SX and Carbylan-GSX in rabbit vocal fold wound healing model)
- IT Collagens, biological studies
 - RL: BSU (Biological study, unclassified); BIOL (Biological study) (procollagens, type I; expression level of procollagen type 1 mRNA was not affected by Carbylan-SX and Carbylan-SX in rabbit vocal fold wound
 - healing model) IT Wound healing
 - Would learning (synthetic extracellular matrix Carbylan-GSX exhibited optimal biol. and biomech. properties and promoted wound repair and tissue regeneration in rabbit vocal fold wound healing model)
- IT Larynx
 - (vocal cord; synthetic extracellular matrix Carbylan-GSX exhibited optimal biol. and biomech. properties and promoted wound repair and tiesue regeneration in rabbit vocal fold wound healing model) 37326-33-3, Hyaluronoqlucosaminidase
- 1 3/326-33-3, Hyaruronogrucosaminidase
 - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Carbylan-GSX increased hyaluronidase 2 mRNA level in rabbit vocal fold wound healing model)
- IT 855126-79-3, Carbylan SX
- RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (Carbylan-SX was less effective than Carbylan-GSX in providing environment for wound healing in rabbit vocal fold wound healing model)
- IT 39346-43-5, Hyaluronic acid synthase RL: BSU (Biological study, unclassified); BIOL (Biological study) (expression level of hyaluronic acid synthase 2 mRNA was not affected
- by Carbylan-SX and Carbylan-GSX in rabbit vocal fold wound healing model)
- IT 855126-78-2, Carbylan GSX
 - RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (synthetic extracellular matrix Carbylan-GSX exhibited optimal biol. and biomech. properties and promoted wound repair and tissue regeneration in rabbit vocal fold wound healing model)
- L15 5 ANSWERS HCAPLUS COPYRIGHT 2010 ACS on STN
- CC 63-7 (Pharmaceuticals)

- Oxidized Chondroitin Sulfate-Cross-Linked Gelatin Matrixes: A New Class of Hydrogels
- chondroitin sulfate gelatin crosslinking hydrogel
- TT Biocompatibility

Crosslinking Hydrogels

Swelling, physical

Water vapor

Wound healing

(cross-linked hydrogel from oxidized chondroitin sulfate and gelatin) Gelatins, biological studies

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cross-linked hydrogel from oxidized chondroitin sulfate and gelatin) Medical goods

(dressings; cross-linked hydrogel from oxidized chondroitin sulfate and delatin) Oxidation

(periodate; cross-linked hydrogel from oxidized chondroitin sulfate and gelatin)

25322-46-7D, Chondroitin-6-sulfate, oxidized

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cross-linked hydrogel from oxidized chondroitin sulfate and gelatin)

- HCAPLUS COPYRIGHT 2010 ACS on STN 5 ANSWERS
- 1-12 (Pharmacology)
 - Hyaluronic acid induces wound closure by primary human skin fibroblasts in a wound healing model
- ST hyaluronic acid skin fibroblast migration wound healing
- ΙT Cell migration

Fibroblast

Human

Wound healing

(hyaluronic acid induced wound closure through regulating migration of human skin fibroblast by stimulating matrix metalloproteinase-2 expression in wound healing model)

146480-35-5, Matrix metalloproteinase-2

RL: BSU (Biological study, unclassified); BIOL (Biological study) (hyaluronic acid induced wound closure through regulating migration of human skin fibroblast by stimulating matrix metalloproteinase-2 expression in wound healing model)

9004-61-9, Hvaluronic acid

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(hyaluronic acid induced wound closure through regulating migration of human skin fibroblast by stimulating matrix metalloproteinase-2 expression in wound healing model)

- L15 5 ANSWERS HCAPLUS COPYRIGHT 2010 ACS on STN
- 1-12 (Pharmacology)
 - Dermatan sulfate induces matrix metalloproteinase-2 and stimulates the migration of human primary fibroblasts
- dermatan sulfate hvaluronic acid chondroitin sulfate cell migration; matrix metalloproteinase2 wound healing promoter
- Cell migration

Fibroblast

Human

Lung

Wound healing

Wound healing promoters

(glycosaminoglycan dermatan sulfate, hyaluronic acid but not

chondroitin sulfate A or chondroitin sulfate B time, dose-dependently increased MMP-2 secretion and stimulated cell migration towards wound area in human lung fibroblast)

24967-93-9, Chondroitin sulfate A

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chondroitin sulfate A did not stimulated cell migration towards wound area in human lung fibroblast)

25322-46-7, Chondroitin sulphate C

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(chondroitin sulfate B did not stimulated cell migration towards wound area in human lung fibroblast)

146480-35-5, Matrix metalloproteinase-2

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(glycosaminoglycan dermatan sulfate, hyaluronic acid but not chondroitin sulfate A or chondroitin sulfate B time, dose-dependently increased MMP-2 secretion in human lung fibroblast)

24967-94-0, Dermatan sulfate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(glycosaminoglycan like dermatan sulfate time and dose-dependently increased MMP-2 secretion and stimulated cell migration towards wound area in human lung fibroblast)

9004-61-9, Hyaluronic acid

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(glycosaminoglycan like hyaluronic acid time and dose-dependently increased MMP-2 secretion and stimulated cell migration towards wound area in human lung fibroblast)

ALL ANSWERS HAVE BEEN SCANNED

=> d 115 ibib kwic 1-

SOURCE:

YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):v

L15 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:812052 HCAPLUS

DOCUMENT NUMBER: 149:167878

TITLE: Hyaluronic acid induces wound closure by primary human skin fibroblasts in a wound healing model

AUTHOR(S): Economou, D.; Papakonstantinou, E.; Klagas, I.; Sakadamis, Ath.; Sioga, A.

Department of Histology-Embryology, School of CORPORATE SOURCE:

Medicine, Aristotle University of Thessaloniki, Greece

Epitheorese Klinikes Farmakologias kai Farmakokinetikes, International Edition (2008), 22(2),

138-140

CODEN: EFKEEB; ISSN: 1011-6583

PUBLISHER: Pharmakon-Press DOCUMENT TYPE: Journal

LANGUAGE: English

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 10 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Hyaluronic acid (HA) is the most common glycosaminoglycan present in the extracellular matrix of epidermis and dermis. In the present study, we investigated the effect of HA on the migration of

primary human skin fibroblasts in a wound healing model. We found that HA (1 .mu.g/mL) enhances in a time-dependent manner (2-48 h) the migration of human skin fibroblasts.. . . was assocd. with

an increased secretion of MMP-2 gelatinolytic activity and an induction in MMP-2 gene expression, as assessed by gelatin zymog. and RT-PCR, resp. Our results indicate that HA regulates the migration of human skin fibroblasts by stimulation of MMP-2 and may offer an addnl. target for pharmacol, intervention in wound healing,

L15 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:937262 HCAPLUS

DOCUMENT NUMBER: 146:428308

TITLE: Vocal Fold Tissue Repair in Vivo Using a Synthetic

Extracellular Matrix

AUTHOR(S): Duflo, Suzy; Thibeault, Susan L.; Li, Wenhua; Shu,

Xiao Zheng; Prestwich, Glenn D. CORPORATE SOURCE:

Head and Neck Surgery, Federation d'Otorhinolaryngology, Hopital de la Timone,

Marseille, Fr.

Tissue Engineering (2006), 12(8), 2171-2180 SOURCE .

CODEN: TIENFP; ISSN: 1076-3279

PUBLISHER: Mary Ann Liebert, Inc.

DOCUMENT TYPE: Journal LANGUAGE: English

OS.CITING REF COUNT: 26 THERE ARE 26 CAPLUS RECORDS THAT CITE THIS

RECORD (26 CITINGS)

THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 55 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Chem. modified hyaluronic acid (HA)-gelatin hydrogels have been documented to support attachment, growth, and proliferation of fibroblasts in vitro and to facilitate repair and engineering. . . of a synthetic extracellular matrix (sECM) that would promote wound repair and induce tissue regeneration in a rabbit vocal fold wound healing model. The sECM was formed using a thiol-modified semisynthetic glycosaminoglycan (GAG) derived of HA (Carbylan-SX) mixed with a thiolated gelatin deriv., co-cross-linked with poly(ethylene glycol) diacrylate to form Carbylan-GSX. Forty rabbits underwent vocal fold biopsy bilaterally. Rabbits were treated with Carbylan-SX, which lacks gelatin, or with Carbylan-GSX with different gelatin concns. (2.5%, 5%, 10%, and 20%) via unilateral injection of the vocal fold at the time of biopsy. Saline was. . . 2, and tissue biomechanics were evaluated. Hyaluronidase mRNA levels were found to be significantly elevated in for Carbylan-GSX 20% wt./wt. gelatin

compared to controls. Both Carbylan-SX and Carbylan-GSX significantly improved tissue elasticity and viscosity. Carbylan-GSX contg. 5% wt./wt. gelatin showed the most promise as a scaffold material for vocal fold tissue regeneration.

L15 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2006:581463 HCAPLUS

DOCUMENT NUMBER: 145:432131

TITLE: Dermatan sulfate induces matrix metalloproteinase-2 and stimulates the migration of human primary

fibroblasts

AUTHOR(S): Sioga, A.; Economou, D.; Varinou, L.; Klangas, I.; Papakonstantinou, E.; Economou, L.; Karakiulakis, G.

Department of Histology-Embryology, School of CORPORATE SOURCE:

Medicine, Aristotle University of Thessaloniki, Greece SOURCE: Epitheorese Klinikes Farmakologias kai

Farmakokinetikes, International Edition (2006), 20(2),

319-321

CODEN: EFKEEB; ISSN: 1011-6583

PUBLISHER: Pharmakon-Press Journal DOCUMENT TYPE:

LANGUAGE: English AB Glycosaminoglycans are extracellular matrix mols. which mediate a no. of cellular functions such as proliferation, migration and response to growth factors. . . (CSA), dermatan sulfate (DS), chondroitin sulfate (CSC) and HA on the migration of primary human lung fibroblasts in a wound healing model. We found that DS and HA stimulate in a dose- (1-50 .mu.g) and time-(4-48 h) dependent manner the migration of fibroblasts. The DS-induced migration coincides with enhanced secretion of MMP-2, as revealed by gelatin zymog. in aliquots of the supernatants of cell cultures. Our results indicate that DS is involved in the migration of fibroblasts and the secretion of MMP-2, and may offer an alternative target for pharmacol. intervention in the process of wound healing.

L15 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:315162 HCAPLUS

DOCUMENT NUMBER: 143:32125

TITLE: Oxidized Chondroitin Sulfate-Cross-Linked Gelatin

Matrixes: A New Class of Hydrogels

AUTHOR(S): Dawlee, S.; Sugandhi, A.; Balakrishnan, Biji; Labarre,

D.; Jayakrishnan, A.

CORPORATE SOURCE: Polymer Chemistry Division, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Kerala, 695 012, India

SOURCE: Biomacromolecules (2005), 6(4), 2040-2048

CODEN: BOMAF6; ISSN: 1525-7797
PUBLISHER: American Chemical Society

AB A naturally occurring glycosaminoglycan such as

DOCUMENT TYPE: Journal

LANGUAGE: English

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS

RECORD (10 CITINGS)

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

chondroitin-6-sulfate was first converted in to its aldehyde deriv. by periodate oxidn. and used as a crosslinking agent for gelatin giving rise to a new class of hydrogels. Crosslinking was predominantly due to Schiff's base formation between the .epsilon.-amino groups of lysine or hydroxylysine side groups of gelatin and the aldehyde groups in oxidized chondroitin sulfate. The hydrogels were prepd. chondroitin sulfate with different degrees of oxidn. and gelatin. They were characterized for degree of crosslinking, crosslinking d., equil. swelling, water vapor transmission rate, internal structure, and blood-compatibility. Degree. 90% water and did not undergo dehydration rapidly. The hydrogels were nontoxic and blood-compatible. Since an important phase of early wound healing has been shown to involve secretion of glycosaminoglycans such as chondroitin sulfate by fibroblasts which form a hydrophilic matrix

suitable for remodeling during healing, this new class of hydrogels prepd.

L15 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1986:614123 HCAPLUS DOCUMENT NUMBER: 105:214123

ORIGINAL REFERENCE NO.: 105:34441a,34444a
TITLE: 105:34441a,34444a
Crosslinked glycosaminoglycan composites as artificial

from chondroitin sulfate and gelatin without employing any extraneous crosslinking agents are expected to have potential as wound

ILE: CIOSSI.

dressing materials.

INVENTOR(S): Sakurai, Katsukyo; Ueno, Yoshio PATENT ASSIGNEE(S): Seikagaku Kogyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61154567	A	19860714	JP 1984-273492	19841226
JP 05086234	В	19931210		
RIORITY APPLN. INFO.:			JP 1984-273492	19841226

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

Composites of crosslinked glycosaminoglycans with collagens or gelatins are prepd. for use as an artificial organ. Thus, Na hyaluronate was crosslinked using epichlorohydrin. To the sol. crosslinked hyaluronic. . . and dried to have a thickness of 0.003 cm. The film covered on the skin lesion area in rats stimulated wound

=> s (wound healing) (p) (polvoxvethylene) (p) (gelatin)

81106 WOUND

healing.

12781 WOUNDS

84977 WOUND

(WOUND OR WOUNDS)

52103 HEALING

39 HEALINGS

52122 HEALING

(HEALING OR HEALINGS)

32480 WOUND HEALING

(WOUND(W)HEALING) 57172 POLYOXYETHYLENE

640 POLYOXYETHYLENES

57373 POLYOXYETHYLENE

(POLYOXYETHYLENE OR POLYOXYETHYLENES)

79322 GELATIN 39507 GELATINS

94998 GELATIN

(GELATIN OR GELATINS)

1 (WOUND HEALING) (P) (POLYOXYETHYLENE) (P) (GELATIN)

L17 => d 117

L17 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2010 ACS on STN

AN 1986:213019 HCAPLUS

DN 104:213019

OREF 104:33665a,33668a

TΙ Topical preparations containing urea and collagen Yanagida, Takeshi

IN

PA Shiseido Co., Ltd., Japan

Jpn. Kokai Tokkyo Koho, 4 pp. SO

CODEN: JKXXAF Patent

Japanese

LA ENN CHT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
PI PRAI	JP 61033105 JP 1984-153795	A	19860217 19840724	JP 1984-153795	19840724		

- L17 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2010 ACS on STN
- AB Prepns. for skin application contain urea (softening, cell activation, wound healing), and collagen and(or) its hydrolysis products (gelatin and others) as stabilizer. Thus, an emollient contained glycerin 20.0, propylene glycol 8.0, EtOH 5.0, polyoxyethylene olev1 ether 0.5, carboxyvinv1 polymer 0.5, urea 1.0, Gelatin-1 3.0 Desamino Collagen 3.0, and perfumes and purified H2O to 100%.

=> d his full

(FILE 'HOME' ENTERED AT 09:45:57 ON 10 SEP 2010)

FILE 'HCAPLUS' ENTERED AT 09:49:11 ON 10 SEP 2010

- 16 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (5A) GELATIN AND (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (5A) GELATIN
- 41 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN
- 7 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON L3 (2A) CROSS (2A) LINKED) (P) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN (P) MIXTURE D L3 IBIB KWIC 1-
- L4 0 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) GELATIN AND (SWOLLEN OR COLLOID OR HYDROCOLLOID OR COLLOIDAL) (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN
- 4 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) GELATIN AND (GEL OR GELLED) (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN D L5 IBIB 1-
 - D L5 4 IBIB KWIC
- L6 0 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) GELATIN AND (FRAGMENT OR FRAGMENTED OR DISRUPTED OR PARTICLE OR PARTICULATE) (P) (GEL OR GELLED) (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN
- L7 0 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) GELATIN AND (FRAGMENT OR FRAGMENTED OR DISRUPTED OR PARTICLE OR PARTICULATE) (P) (HYDRATED) (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN
- L8 3 SEA ABB=ON PLU=ON (NONCROSSLINKED OR NON-CROSSLINKED OR NON (2A) CROSS (2A) LINKED) (P) GELATIN AND (FRAGMENT OR FRAGMENTED OR DISRUPTED OR PARTICLE OR PARTICULATE) (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN D L8 IBIB KWIC 1-
- L9
- L10
- L11
- O SEA ABB-ON PLU-ON L3 AND POLYOXYETHYLENE
 O SEA ABB-ON PLU-ON L3 AND GLUCOSAMINOGLYCAN
 O SEA ABB-ON PLU-ON L3 AND DEXTRAN
 9 SEA ABB-ON PLU-ON (FRAGMENT OR FRAGMENTED OR DISRUPTED OR PARTICLE OR PARTICULATE) (P) (HYDROGEL OR HYDROCOLLOIDAL OR HYDROCOLLOID OR HYDRATED) (5A) (CROSSLINKED OR CROSS (2A) LINKED OR CROSS-LINKED) (P) GELATIN
- 1.13 3 SEA ABB=ON PLU=ON L12 AND (DEXTRAN OR GLYCOSAMINOGLYCAN OR POLYSACCHARIDE) D L13 IBIB KWIC 1-

L14	281 SEA ABB=ON PLU=ON	(WOUND HEALING) (P) (GLYCOSAMINOGLYCAN)
L15	5 SEA ABB=ON PLU=ON	(WOUND HEALING) (P) (GLYCOSAMINOGLYCAN)
	(P) (GELATIN)	
L16	0 SEA ABB=ON PLU=ON	L15 AND POLYOXYETHYLENE
	D L15 SCAN	
	D L15 IBIB KWIC 1-	
L17	1 SEA ABB=ON PLU=ON	(WOUND HEALING) (P) (POLYOXYETHYLENE) (P)
	(GELATIN)	
	D L17	

FILE HOME

FILE HCAPLUS

D L17 KWIC

Copyright of the articles to which records in this database refer is held by the publishere listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Sep 2010 VOL 153 ISS 12
FILE LAST UPDATED: 9 Sep 2010 (20100909/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> log h		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	136.41	137.73
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS		TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-16.15	-16.1

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:03:46 ON 10 SEP 2010